Drug Design for CNS Diseases: Polypharmacological Profiling of Compounds Using Cheminformatic, 3D-QSAR and Virtual Screening Methodologies
暂无分享,去创建一个
John B. O. Mitchell | K. Nikolić | L. Mavridis | Teodora Djikić | J. Vučićević | D. Agbaba | K. Yelekçi
[1] R. M. Muir,et al. Correlation of Biological Activity of Phenoxyacetic Acids with Hammett Substituent Constants and Partition Coefficients , 1962, Nature.
[2] E. Parzen. On Estimation of a Probability Density Function and Mode , 1962 .
[3] P N Craig. Interdependence between physical parameters and selection of substituent groups for correlation studies. , 1971, Journal of medicinal chemistry.
[4] P. N. Craig,et al. Interdependence between physical parameters and selection of substituent groups for correlation studies. , 1971, Journal of medicinal chemistry.
[5] J. Newhouse. Is Collinearity a Problem , 1971 .
[6] J. Topliss,et al. Utilization of operational schemes for analog synthesis in drug design. , 1972, Journal of medicinal chemistry.
[7] A B Forsythe,et al. Strategy in drug design. Cluster analysis as an aid in the selection of substituents. , 1973, Journal of medicinal chemistry.
[8] Alan B. Forsythe,et al. Strategy in drug design. Cluster anlysis as an aid in the selection of substituents , 1973 .
[9] A. Verloop,et al. Development and Application of New Steric Substituent Parameters in Drug Design , 1976 .
[10] S. Wold,et al. The Collinearity Problem in Linear Regression. The Partial Least Squares (PLS) Approach to Generalized Inverses , 1984 .
[11] P. Goodford. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. , 1985, Journal of medicinal chemistry.
[12] R. Cramer,et al. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. , 1988, Journal of the American Chemical Society.
[13] A. Carlsson,et al. Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease , 1990, Trends in Neurosciences.
[14] H. Soininen,et al. Neurotransmitter changes in alzheimer's disease: Implications to diagnostics and therapy , 1990, Journal of neuroscience research.
[15] G. Klebe,et al. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. , 1994, Journal of medicinal chemistry.
[16] R. Abagyan,et al. Biased probability Monte Carlo conformational searches and electrostatic calculations for peptides and proteins. , 1994, Journal of molecular biology.
[17] R. Glen,et al. Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. , 1995, Journal of molecular biology.
[18] K. E. Newhouse. Goodman and Gilman's The Pharmacological Basis of Therapeutics , 1986, The Yale Journal of Biology and Medicine.
[19] Thomas Lengauer,et al. Computational methods for biomolecular docking. , 1996, Current opinion in structural biology.
[20] David S. Goodsell,et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998 .
[21] David S. Goodsell,et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998, J. Comput. Chem..
[22] J. Schwartz,et al. Neurochemical and behavioral effects of ciproxifan, a potent histamine H3-receptor antagonist. , 1998, The Journal of pharmacology and experimental therapeutics.
[23] G. Sedvall,et al. Pharmacological Manipulation of D1-Dopamine Receptor Function in Schizophrenia , 1999, Neuropsychopharmacology.
[24] M. Unzeta,et al. Relevance of benzyloxy group in 2‐indolyl methylamines in the selective MAO‐B inhibition , 1999, British journal of pharmacology.
[25] Janet M. Thornton,et al. BLEEP - potential of mean force describing protein-ligand interactions: I. Generating potential , 1999, J. Comput. Chem..
[26] S. Pickett,et al. GRid-INdependent descriptors (GRIND): a novel class of alignment-independent three-dimensional molecular descriptors. , 2000, Journal of medicinal chemistry.
[27] M. Tozer,et al. Histamine H3 receptor antagonists , 2000 .
[28] T. N. Bhat,et al. The Protein Data Bank , 2000, Nucleic Acids Res..
[29] C R Ganellin,et al. Distinct pharmacology of rat and human histamine H3 receptors: role of two amino acids in the third transmembrane domain , 2000, British journal of pharmacology.
[30] J. Bourne,et al. SCH 23390: the first selective dopamine D1-like receptor antagonist. , 2006, CNS drug reviews.
[31] D J Diller,et al. High throughput docking for library design and library prioritization , 2001, Proteins.
[32] Holger Stark,et al. Development of a new class of nonimidazole histamine H(3) receptor ligands with combined inhibitory histamine N-methyltransferase activity. , 2002, Journal of medicinal chemistry.
[33] G. Klebe,et al. DrugScore meets CoMFA: adaptation of fields for molecular comparison (AFMoC) or how to tailor knowledge-based pair-potentials to a particular protein. , 2002, Journal of medicinal chemistry.
[34] G. Remington. Understanding antipsychotic "atypicality": a clinical and pharmacological moving target. , 2003, Journal of psychiatry & neuroscience : JPN.
[35] Aripiprazole: efficacy and tolerability profile of a novel-acting atypical antipsychotic. , 2003, Drugs of today.
[36] R. Mailman,et al. Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology , 2003, Neuropsychopharmacology.
[37] Charles L. Brooks,et al. Detailed analysis of grid‐based molecular docking: A case study of CDOCKER—A CHARMm‐based MD docking algorithm , 2003, J. Comput. Chem..
[38] Egon L. Willighagen,et al. The Chemistry Development Kit (CDK): An Open-Source Java Library for Chemo-and Bioinformatics , 2003, J. Chem. Inf. Comput. Sci..
[39] J. Schwartz,et al. Imidazole derivatives as a novel class of hybrid compounds with inhibitory histamine N-methyltransferase potencies and histamine hH3 receptor affinities. , 2003, Bioorganic & medicinal chemistry.
[40] J. Alvarez. High-throughput docking as a source of novel drug leads. , 2004, Current opinion in chemical biology.
[41] Leo Breiman,et al. Random Forests , 2001, Machine Learning.
[42] J. Witkin,et al. Selective histamine H3 receptor antagonists for treatment of cognitive deficiencies and other disorders of the central nervous system. , 2004, Pharmacology & therapeutics.
[43] J. Schwartz,et al. Search for Histamine H3 Receptor Ligands with Combined Inhibitory Potency at Histamine N‐Methyltransferase: ω‐Piperidinoalkanamine Derivatives , 2004, Archiv der Pharmazie.
[44] S. Cragg,et al. Histamine H3 Receptors Inhibit Serotonin Release in Substantia Nigra Pars Reticulata , 2004, The Journal of Neuroscience.
[45] B. Roth,et al. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia , 2004, Nature Reviews Drug Discovery.
[46] Andreas Bender,et al. Molecular Similarity Searching Using Atom Environments, Information-Based Feature Selection, and a Naïve Bayesian Classifier , 2004, J. Chem. Inf. Model..
[47] G. Reynolds. Receptor Mechanisms in the treatment of Schizophrenia , 2004, Journal of psychopharmacology.
[48] Paul D Leeson,et al. Time-related differences in the physical property profiles of oral drugs. , 2004, Journal of medicinal chemistry.
[49] R. Carnahan,et al. Aripiprazole, a Novel Atypical Antipsychotic Drug , 2004, Pharmacotherapy.
[50] J. Bajorath,et al. Docking and scoring in virtual screening for drug discovery: methods and applications , 2004, Nature Reviews Drug Discovery.
[51] Alan A. Wilson,et al. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics. , 2004, The American journal of psychiatry.
[52] Jerry J Buccafusco,et al. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. , 2005, Trends in pharmacological sciences.
[53] R. Morphy,et al. Designed multiple ligands. An emerging drug discovery paradigm. , 2005, Journal of medicinal chemistry.
[54] M. Millan. N-Methyl-d-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives , 2005, Psychopharmacology.
[55] Janet M. Thornton,et al. ProFunc: a server for predicting protein function from 3D structure , 2005, Nucleic Acids Res..
[56] D. Eisenberg,et al. Inference of protein function from protein structure. , 2005, Structure.
[57] J. Schwartz,et al. Search for histamine H3 receptor antagonists with combined inhibitory potency at Ntau-methyltransferase: ether derivatives. , 2005, Die Pharmazie.
[58] William J Greenlee,et al. Dopamine D1/D5 receptor antagonists with improved pharmacokinetics: design, synthesis, and biological evaluation of phenol bioisosteric analogues of benzazepine D1/D5 antagonists. , 2005, Journal of medicinal chemistry.
[59] M. Millan. Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. , 2006, Pharmacology & therapeutics.
[60] J. Lehmann,et al. Dibenzazecine compounds with a novel dopamine/5HT2A receptor profile and 3D-QSAR analysis , 2006, BMC pharmacology.
[61] Pedro Alexandrino Fernandes,et al. Protein–ligand docking: Current status and future challenges , 2006, Proteins.
[62] Keith F. Tipton,et al. The therapeutic potential of monoamine oxidase inhibitors , 2006, Nature Reviews Neuroscience.
[63] José Marco-Contelles,et al. Novel multipotent tacrine-dihydropyridine hybrids with improved acetylcholinesterase inhibitory and neuroprotective activities as potential drugs for the treatment of Alzheimer's disease. , 2006, Journal of medicinal chemistry.
[64] S. Hitchcock,et al. Structure-brain exposure relationships. , 2006, Journal of medicinal chemistry.
[65] Steven L Dixon,et al. PHASE: A Novel Approach to Pharmacophore Modeling and 3D Database Searching , 2006, Chemical biology & drug design.
[66] M. Goedert,et al. A Century of Alzheimer's Disease , 2006, Science.
[67] C. E. Peishoff,et al. A critical assessment of docking programs and scoring functions. , 2006, Journal of medicinal chemistry.
[68] Geri A. Sawada,et al. Early Preclinical Evaluation of Brain Exposure in Support of Hit Identification and Lead Optimization , 2006 .
[69] Multiple enzyme inhibitions by histamine H3 receptor antagonists as potential procognitive agents. , 2006, Die Pharmazie.
[70] R. Leurs,et al. The histamine H3 receptor antagonist clobenpropit enhances GABA release to protect against NMDA-induced excitotoxicity through the cAMP/protein kinase A pathway in cultured cortical neurons. , 2007, European journal of pharmacology.
[71] M. Decker. Recent advances in the development of hybrid molecules/designed multiple compounds with antiamnesic properties. , 2007, Mini reviews in medicinal chemistry.
[72] J. Arrang,et al. Histamine H3 and dopamine D2 receptor-mediated [35S]GTPgamma[S] binding in rat striatum: evidence for additive effects but lack of interactions. , 2007, Biochemical pharmacology.
[73] Jürgen Bajorath,et al. Molecular similarity analysis in virtual screening: foundations, limitations and novel approaches. , 2007, Drug discovery today.
[74] P. Leeson,et al. The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.
[75] M. Treviño,et al. Pre-synaptic histamine H3 receptors regulate glutamate, but not GABA release in rat thalamus , 2007, Neuropharmacology.
[76] Angelo Carotti,et al. Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs. , 2007, Journal of medicinal chemistry.
[77] A. Bender,et al. Analysis of Pharmacology Data and the Prediction of Adverse Drug Reactions and Off‐Target Effects from Chemical Structure , 2007, ChemMedChem.
[78] Holger Stark,et al. Histamine H3 receptor antagonists go to clinics. , 2008, Biological & pharmaceutical bulletin.
[79] F. Prado-Prado,et al. Predicting antimicrobial drugs and targets with the MARCH-INSIDE approach. , 2008, Current topics in medicinal chemistry.
[80] G. Morris,et al. Molecular docking. , 2008, Methods in molecular biology.
[81] Olivier Sperandio,et al. Combining Ligand- and Structure-Based Methods in Drug Design Projects , 2008 .
[82] Jaques Reifman,et al. DOVIS 2.0: an efficient and easy to use parallel virtual screening tool based on AutoDock 4.0 , 2008, Chemistry Central journal.
[83] K. Browman,et al. The histamine H3 receptor: an attractive target for the treatment of cognitive disorders , 2008, British journal of pharmacology.
[84] Hanna Geppert,et al. Integrating Structure‐ and Ligand‐Based Virtual Screening: Comparison of Individual, Parallel, and Fused Molecular Docking and Similarity Search Calculations on Multiple Targets , 2008, ChemMedChem.
[85] Angelo D. Favia,et al. Molecular docking for substrate identification: the short-chain dehydrogenases/reductases. , 2008, Journal of molecular biology.
[86] A. Hopkins. Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.
[87] E. Esposito,et al. Serotonin-dopamine interaction: electrophysiological evidence. , 2008, Progress in brain research.
[88] E. Esposito,et al. Serotonin control of central dopaminergic function: focus on in vivo microdialysis studies. , 2008, Progress in brain research.
[89] E. Yamashita,et al. Structure of human monoamine oxidase A at 2.2-Å resolution: The control of opening the entry for substrates/inhibitors , 2008, Proceedings of the National Academy of Sciences.
[90] M. Gleeson. Generation of a set of simple, interpretable ADMET rules of thumb. , 2008, Journal of medicinal chemistry.
[91] J. Mestres,et al. Conciliating binding efficiency and polypharmacology. , 2009, Trends in pharmacological sciences.
[92] Xavier Barril,et al. Tacripyrines, the first tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer's disease. , 2009, Journal of medicinal chemistry.
[93] B. Ellenbroek,et al. The histamine H3 receptor as a therapeutic drug target for CNS disorders. , 2009, Drug discovery today.
[94] H. Stark,et al. Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics. , 2009, Bioorganic & medicinal chemistry letters.
[95] Ismael Zamora,et al. Suitability of GRIND-Based Principal Properties for the Description of Molecular Similarity and Ligand-Based Virtual Screening , 2009, J. Chem. Inf. Model..
[96] David S. Goodsell,et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility , 2009, J. Comput. Chem..
[97] Bin Chen,et al. PubChem as a Source of Polypharmacology , 2009, J. Chem. Inf. Model..
[98] Nanda Ghoshal,et al. Hybrid Structure-Based Virtual Screening Protocol for the Identification of Novel BACE1 Inhibitors , 2009, J. Chem. Inf. Model..
[99] George Karypis,et al. Multi-Assay-Based Structure-Activity Relationship Models: Improving Structure-Activity Relationship Models by Incorporating Activity Information from Related Targets , 2009, J. Chem. Inf. Model..
[100] Zhi Chen,et al. Multiple Pharmacophore Models Combined with Molecular Docking: A Reliable Way for Efficiently Identifying Novel PDE4 Inhibitors with High Structural Diversity , 2010, J. Chem. Inf. Model..
[101] W. Geldenhuys,et al. Virtual screening to identify novel antagonists for the G protein-coupled NK3 receptor. , 2010, Journal of medicinal chemistry.
[102] M. Reith,et al. Bivalent phenethylamines as novel dopamine transporter inhibitors: evidence for multiple substrate‐binding sites in a single transporter , 2010, Journal of neurochemistry.
[103] Lazaros Mavridis,et al. Comprehensive Comparison of Ligand-Based Virtual Screening Tools Against the DUD Data set Reveals Limitations of Current 3D Methods , 2010, J. Chem. Inf. Model..
[104] C. Sotriffer,et al. Docking compared to 3D-pharmacophores: the scoring function challenge , 2010 .
[105] R. Iyengar,et al. Systems approaches to polypharmacology and drug discovery. , 2010, Current opinion in drug discovery & development.
[106] Hsuan-Liang Liu,et al. The discovery of potential acetylcholinesterase inhibitors: A combination of pharmacophore modeling, virtual screening, and molecular docking studies , 2011, Journal of Biomedical Science.
[107] Richard A. Lewis,et al. Three-dimensional pharmacophore methods in drug discovery. , 2010, Journal of medicinal chemistry.
[108] Daniela Schuster,et al. 3D pharmacophores as tools for activity profiling. , 2010, Drug discovery today. Technologies.
[109] Marcelo Santos Castilho,et al. Discovery of New Inhibitors of Schistosoma mansoni PNP by Pharmacophore-Based Virtual Screening , 2010, J. Chem. Inf. Model..
[110] Marc C Nicklaus,et al. Inhibitors of human tyrosyl-DNA phospodiesterase (hTdp1) developed by virtual screening using ligand-based pharmacophores. , 2010, Bioorganic & medicinal chemistry.
[111] K. Bui,et al. Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate. , 2010, Bioorganic & medicinal chemistry letters.
[112] J. Bajorath,et al. Quo vadis, virtual screening? A comprehensive survey of prospective applications. , 2010, Journal of medicinal chemistry.
[113] M. Youdim,et al. Site-Activated Chelators Derived from Anti-Parkinson Drug Rasagiline as a Potential Safer and More Effective Approach to the Treatment of Alzheimer’s Disease , 2010, Neurochemical Research.
[114] Eva Schmidt,et al. Cariprazine (RGH-188), a Dopamine D3 Receptor-Preferring, D3/D2 Dopamine Receptor Antagonist–Partial Agonist Antipsychotic Candidate: In Vitro and Neurochemical Profile , 2010, Journal of Pharmacology and Experimental Therapeutics.
[115] Shahnaz Perveen,et al. Identification of potent urease inhibitors via ligand- and structure-based virtual screening and in vitro assays. , 2010, Journal of molecular graphics & modelling.
[116] Alexander Golbraikh,et al. Development, validation, and use of quantitative structure-activity relationship models of 5-hydroxytryptamine (2B) receptor ligands to identify novel receptor binders and putative valvulopathic compounds among common drugs. , 2010, Journal of medicinal chemistry.
[117] Klaus R. Liedl,et al. One Concept, Three Implementations of 3D Pharmacophore-Based Virtual Screening: Distinct Coverage of Chemical Search Space , 2010, J. Chem. Inf. Model..
[118] Violeta I. Pérez-Nueno,et al. Improving VEGFR-2 Docking-Based Screening by Pharmacophore Postfiltering and Similarity Search Postprocessing , 2011, J. Chem. Inf. Model..
[119] Bernd Wellenzohn,et al. Ligand‐Based Virtual Screening , 2011 .
[120] Malgorzata N. Drwal,et al. Exploring DNA Topoisomerase I Ligand Space in Search of Novel Anticancer Agents , 2011, PloS one.
[121] David S. Wishart,et al. DrugBank 3.0: a comprehensive resource for ‘Omics’ research on drugs , 2010, Nucleic Acids Res..
[122] Richard A. Davis,et al. Remarks on Some Nonparametric Estimates of a Density Function , 2011 .
[123] Discovery of PF-00217830: aryl piperazine napthyridinones as D2 partial agonists for schizophrenia and bipolar disorder. , 2011, Bioorganic & medicinal chemistry letters.
[124] B. Erman. Relationships between ligand binding sites, protein architecture and correlated paths of energy and conformational fluctuations , 2011, Physical biology.
[125] Jano I. van Hemert,et al. EnzML: multi-label prediction of enzyme classes using InterPro signatures , 2012, BMC Bioinformatics.
[126] Scott P. Brown,et al. A unified, probabilistic framework for structure- and ligand-based virtual screening. , 2011, Journal of medicinal chemistry.
[127] Claudio N Cavasotto,et al. Homology models in docking and high-throughput docking. , 2011, Current topics in medicinal chemistry.
[128] Irene Bolea,et al. Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease. , 2011, Journal of medicinal chemistry.
[129] M. Bajda,et al. Multi-target-directed ligands in Alzheimer's disease treatment. , 2011, Current medicinal chemistry.
[130] H. Pajouhesh,et al. Medicinal chemical properties of successful central nervous system drugs , 2005, NeuroRX.
[131] Alexander D. MacKerell,et al. Recent advances in ligand-based drug design: relevance and utility of the conformationally sampled pharmacophore approach. , 2011, Current computer-aided drug design.
[132] Gregory L. Wilson,et al. Integrating structure-based and ligand-based approaches for computational drug design. , 2011, Future medicinal chemistry.
[133] W. Pardridge. The blood-brain barrier: Bottleneck in brain drug development , 2005, NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics.
[134] Philip E. Bourne,et al. A Machine Learning-Based Method To Improve Docking Scoring Functions and Its Application to Drug Repurposing , 2011, J. Chem. Inf. Model..
[135] Richard D. Cramer,et al. The inevitable QSAR renaissance , 2011, Journal of Computer-Aided Molecular Design.
[136] Christine A. Orengo,et al. Exploiting Protein Structures to Predict Protein Functions , 2011 .
[137] Ajay N. Jain,et al. Iterative Refinement of a Binding Pocket Model: Active Computational Steering of Lead Optimization , 2012, Journal of medicinal chemistry.
[138] H. Meltzer,et al. Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia. , 2012, Current pharmaceutical biotechnology.
[139] Jin-jian Lu,et al. Multi-Target Drugs: The Trend of Drug Research and Development , 2012, PloS one.
[140] B. Guiard,et al. 5-HT 2 ligands in the treatment of anxiety and depression , 2012 .
[141] Arup K. Ghose,et al. Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug Discovery , 2011, ACS chemical neuroscience.
[142] Saskia Nijmeijer,et al. Virtual Fragment Screening: Discovery of Histamine H3 Receptor Ligands Using Ligand-Based and Protein-Based Molecular Fingerprints , 2012, J. Chem. Inf. Model..
[143] J. Roder,et al. Synergistic interactions between PDE4B and GSK-3: DISC1 mutant mice , 2012, Neuropharmacology.
[144] Maria F. Sassano,et al. Automated design of ligands to polypharmacological profiles , 2012, Nature.
[145] Alexander Tropsha,et al. A Chemocentric Informatics Approach to Drug Discovery: Identification and Experimental Validation of Selective Estrogen Receptor Modulators as ligands of 5-Hydroxytryptamine-6 Receptors and as Potential Cognition Enhancers , 2012 .
[146] K. Yelekçi,et al. In silico identification of novel and selective monoamine oxidase B inhibitors , 2012, Journal of Neural Transmission.
[147] Yuan Cheng,et al. Design and preparation of a potent series of hydroxyethylamine containing β-secretase inhibitors that demonstrate robust reduction of central β-amyloid. , 2012, Journal of medicinal chemistry.
[148] Francesco Bossa,et al. Identification by Virtual Screening and In Vitro Testing of Human DOPA Decarboxylase Inhibitors , 2012, PloS one.
[149] B. Guiard,et al. 5-HT2 ligands in the treatment of anxiety and depression , 2012, Expert opinion on investigational drugs.
[150] Humberto González-Díaz,et al. 3D MI-DRAGON: new model for the reconstruction of US FDA drug- target network and theoretical-experimental studies of inhibitors of rasagiline derivatives for AChE. , 2012, Current topics in medicinal chemistry.
[151] John P. Overington,et al. ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..
[152] S. Hitchcock,et al. Structural modifications that alter the P-glycoprotein efflux properties of compounds. , 2012, Journal of medicinal chemistry.
[153] M. Youdim,et al. The novel multi-target iron chelating-radical scavenging compound M30 possesses beneficial effects on major hallmarks of Alzheimer's disease. , 2012, Antioxidants & redox signaling.
[154] Zoran Rankovic,et al. CHAPTER 18:Medicinal Chemistry Challenges in CNS Drug Discovery , 2012 .
[155] Oliver Werz,et al. Identification of novel benzimidazole derivatives as inhibitors of leukotriene biosynthesis by virtual screening targeting 5-lipoxygenase-activating protein (FLAP). , 2012, Bioorganic & medicinal chemistry.
[156] Michael J. Keiser,et al. Large Scale Prediction and Testing of Drug Activity on Side-Effect Targets , 2012, Nature.
[157] Alejandro Panjkovich,et al. Exploiting protein flexibility to predict the location of allosteric sites , 2012, BMC Bioinformatics.
[158] Fredrik Svensson,et al. Virtual Screening Data Fusion Using Both Structure- and Ligand-Based Methods , 2012, J. Chem. Inf. Model..
[159] W. Geldenhuys,et al. A scaffold hopping approach to identify novel monoamine oxidase B inhibitors. , 2012, Bioorganic & medicinal chemistry letters.
[160] José Marco-Contelles,et al. Recent advances in the multitarget‐directed ligands approach for the treatment of Alzheimer's disease , 2013, Medicinal research reviews.
[161] Ian A. Watson,et al. Integration of in silico and in vitro tools for scaffold optimization during drug discovery: predicting P-glycoprotein efflux. , 2013, Molecular pharmaceutics.
[162] J. Roder,et al. Dual inhibitor of PDE7 and GSK-3 – VP1.15 acts as antipsychotic and cognitive enhancer in C57BL/6J mice , 2013, Neuropharmacology.
[163] Lazaros Mavridis,et al. PFClust: a novel parameter free clustering algorithm , 2013, BMC Bioinformatics.
[164] C. Pérez,et al. Multipotent, permeable drug ASS234 inhibits Aβ aggregation, possesses antioxidant properties and protects from Aβ-induced apoptosis in vitro. , 2013, Current Alzheimer research.
[165] Malgorzata N. Drwal,et al. Combination of ligand- and structure-based methods in virtual screening. , 2013, Drug discovery today. Technologies.
[166] R. Boopathy,et al. Identification of potential bivalent inhibitors from natural compounds for acetylcholinesterase through in silico screening using multiple pharmacophores. , 2013, Journal of molecular graphics & modelling.
[167] Yan Zhao,et al. Drug repositioning: a machine-learning approach through data integration , 2013, Journal of Cheminformatics.
[168] Ding Li,et al. 3D-QSAR studies of azaoxoisoaporphine, oxoaporphine, and oxoisoaporphine derivatives as anti-AChE and anti-AD agents by the CoMFA method. , 2013, Journal of molecular graphics & modelling.
[169] Lazaros Mavridis,et al. Predicting the protein targets for athletic performance-enhancing substances , 2013, Journal of Cheminformatics.
[170] Julie Clark,et al. Discovery of Novel Antimalarial Compounds Enabled by QSAR-Based Virtual Screening , 2013, J. Chem. Inf. Model..
[171] J. Peters. Polypharmacology - foe or friend? , 2013, Journal of medicinal chemistry.
[172] Andreas Bender,et al. Modelling ligand selectivity of serine proteases using integrative proteochemometric approaches improves model performance and allows the multi-target dependent interpretation of features. , 2014, Integrative biology : quantitative biosciences from nano to macro.
[173] Markus A. Lill,et al. PharmDock: a pharmacophore-based docking program , 2014, Journal of Cheminformatics.
[174] Gerard J. P. van Westen,et al. Chemical, Target, and Bioactive Properties of Allosteric Modulation , 2014, PLoS Comput. Biol..
[175] Sereina Riniker,et al. Scents and sense: In silico perspectives on olfactory receptors , 2014, J. Comput. Chem..
[176] J. Dearden,et al. QSAR modeling: where have you been? Where are you going to? , 2014, Journal of medicinal chemistry.
[177] M. Millan,et al. On 'polypharmacy' and multi-target agents, complementary strategies for improving the treatment of depression: a comparative appraisal. , 2014, The international journal of neuropsychopharmacology.
[178] Aurélien Lesnard,et al. Dual Histamine H3R/Serotonin 5-HT4R Ligands with Antiamnesic Properties: Pharmacophore-Based Virtual Screening and Polypharmacology , 2014, J. Chem. Inf. Model..
[179] Stefano Alcaro,et al. N-Methyl-N-((1-methyl-5-(3-(1-(2-methylbenzyl)piperidin-4-yl)propoxy)-1H-indol-2-yl)methyl)prop-2-yn-1-amine, a new cholinesterase and monoamine oxidase dual inhibitor. , 2014, Journal of medicinal chemistry.
[180] Na Ye,et al. Dual ligands targeting dopamine D2 and serotonin 5-HT1A receptors as new antipsychotical or anti-Parkinsonian agents. , 2013, Current medicinal chemistry.
[181] Ruben Abagyan,et al. Identification of Novel Serotonin Transporter Compounds by Virtual Screening , 2014, J. Chem. Inf. Model..
[182] R. Rajagopalan,et al. The synthesis and comparative receptor binding affinities of novel, isomeric pyridoindolobenzazepine scaffolds. , 2014, Bioorganic & medicinal chemistry letters.
[183] J. Bajorath,et al. Polypharmacology: challenges and opportunities in drug discovery. , 2014, Journal of medicinal chemistry.
[184] Lazaros Mavridis,et al. Predicting targets of compounds against neurological diseases using cheminformatic methodology , 2015, Journal of Computer-Aided Molecular Design.
[185] Oscar M. Bautista-Aguilera,et al. Design, synthesis, pharmacological evaluation, QSAR analysis, molecular modeling and ADMET of novel donepezil-indolyl hybrids as multipotent cholinesterase/monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease. , 2014, European journal of medicinal chemistry.
[186] Katarina Nikolic,et al. Multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer’s disease: design, synthesis, biochemical evaluation, ADMET, molecular modeling, and QSAR analysis of novel donepezil-pyridyl hybrids , 2014, Drug design, development and therapy.
[187] Hwangseo Park,et al. Consensus Scoring Approach To Identify the Inhibitors of AMP-Activated Protein Kinase α2 with Virtual Screening , 2014, J. Chem. Inf. Model..
[188] Z. Rankovic,et al. Designing CNS Drugs for Optimal Brain Exposure , 2015 .
[189] H. Stark,et al. Pharmacophore modeling, drug design and virtual screening on multi-targeting procognitive agents approaching histaminergic pathways , 2015 .
[190] Dusanka Janezic,et al. LiSiCA: A Software for Ligand-Based Virtual Screening and Its Application for the Discovery of Butyrylcholinesterase Inhibitors , 2015, J. Chem. Inf. Model..
[191] M. Masařík,et al. Virtual screening, ADMET profiling, molecular docking and dynamics approaches to search for potent selective natural molecules based inhibitors against metallothionein-III to study Alzheimer's disease. , 2015, Methods.
[192] S. Günther,et al. Target Fishing by Cross‐Docking to Explain Polypharmacological Effects , 2015, ChemMedChem.
[193] Beáta Flachner,et al. Combination of Pharmacophore Matching, 2D Similarity Search, and In Vitro Biological Assays in the Selection of Potential 5‐HT6 Antagonists from Large Commercial Repositories , 2015, Chemical biology & drug design.
[194] John B. O. Mitchell,et al. Why do Sequence Signatures Predict Enzyme Mechanism? Homology versus Chemistry , 2015, Evolutionary bioinformatics online.
[195] Z. Rankovic,et al. CNS drug design: balancing physicochemical properties for optimal brain exposure. , 2015, Journal of medicinal chemistry.
[196] D. Amato. Serotonin in antipsychotic drugs action , 2015, Behavioural Brain Research.
[197] W. Sippl,et al. Docking and binding free energy calculations of sirtuin inhibitors. , 2015, European journal of medicinal chemistry.
[198] Teodora Djikić,et al. Synthesis and Screening of Human Monoamine Oxidase‐A Inhibitor Effect of New 2‐Pyrazoline and Hydrazone Derivatives , 2015, Archiv der Pharmazie.
[199] Paola Bisignano,et al. Development and Application of a Virtual Screening Protocol for the Identification of Multitarget Fragments , 2016, ChemMedChem.
[200] Lazaros Mavridis,et al. A Random Forest Model for Predicting Allosteric and Functional Sites on Proteins , 2016, Molecular informatics.